Tilray Brands Past Earnings Performance
Past criteria checks 0/6
Tilray Brands's earnings have been declining at an average annual rate of -36.9%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 16.2% per year.
Key information
-36.9%
Earnings growth rate
-17.7%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 16.2% |
Return on equity | -5.8% |
Net Margin | -26.2% |
Next Earnings Update | 09 Jan 2025 |
Recent past performance updates
Recent updates
Tilray Brands May Bounce
Dec 15Here's Why Shareholders May Want To Be Cautious With Increasing Tilray Brands, Inc.'s (NASDAQ:TLRY) CEO Pay Packet
Dec 13Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 26% Price Drop
Dec 05Tilray Brands Is Still Priced Too High
Nov 03Tilray: Another Weed In The Garden
Oct 15Tilray Q1 Preview: Germany Could Drive Earnings Surprise
Oct 08Look For Tilray To Keep Declining
Sep 08Tilray Brands (NASDAQ:TLRY) Is Making Moderate Use Of Debt
Sep 05Tilray Brands, Inc. (NASDAQ:TLRY) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jul 31Tilray Shows Some Nice Improvement In Q4
Jul 30Tilray Should Be Cut From Your Portfolio
Jul 14Why Bears Think Tilray Brands Will Continue To Dip
May 29Tilray Takes A Step Forward
May 21An Intrinsic Calculation For Tilray Brands, Inc. (NASDAQ:TLRY) Suggests It's 34% Undervalued
May 01Tilray Could Break Down
Apr 07Tilray Brands, Inc.'s (NASDAQ:TLRY) Shares Climb 31% But Its Business Is Yet to Catch Up
Mar 27Tilray: Big Opportunities Ahead In Germany And Alcohol Segment
Mar 12Tilray Brands (NASDAQ:TLRY) Is Carrying A Fair Bit Of Debt
Jan 25Tilray Remains Stuck In Neutral
Jan 10Tilray Brands, Inc.'s (NASDAQ:TLRY) Price Is Right But Growth Is Lacking
Dec 19Industry Analysts Just Upgraded Their Tilray Brands, Inc. (NASDAQ:TLRY) Revenue Forecasts By 13%
Oct 10Analysts Are Upgrading Tilray Brands, Inc. (NASDAQ:TLRY) After Its Latest Results
Oct 06Tilray Brands, Inc. (NASDAQ:TLRY) Shares Could Be 22% Below Their Intrinsic Value Estimate
Sep 18Revenue & Expenses Breakdown
How Tilray Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Aug 24 | 812 | -213 | 258 | 1 |
31 May 24 | 789 | -245 | 247 | 1 |
29 Feb 24 | 743 | -368 | 242 | 0 |
30 Nov 23 | 700 | -1,446 | 233 | 0 |
31 Aug 23 | 651 | -1,458 | 229 | 1 |
31 May 23 | 627 | -1,453 | 231 | 1 |
28 Feb 23 | 596 | -1,792 | 228 | 1 |
30 Nov 22 | 603 | -578 | 234 | 1 |
31 Aug 22 | 614 | -501 | 228 | 1 |
31 May 22 | 628 | -477 | 233 | 2 |
28 Feb 22 | 617 | 42 | 217 | 2 |
30 Nov 21 | 589 | -275 | 193 | 2 |
31 Aug 21 | 564 | -375 | 181 | 1 |
31 May 21 | 513 | -367 | 156 | 1 |
28 Feb 21 | 468 | -521 | 143 | 1 |
30 Nov 20 | 462 | -243 | 144 | 1 |
31 Aug 20 | 426 | -149 | 138 | 2 |
31 May 20 | 405 | -103 | 128 | 2 |
29 Feb 20 | 387 | 22 | 117 | 2 |
30 Nov 19 | 338 | -63 | 119 | 1 |
31 Aug 19 | 263 | -16 | 105 | 1 |
31 May 19 | 179 | -25 | 97 | 1 |
28 Feb 19 | 92 | -28 | 80 | 1 |
30 Nov 18 | 43 | 63 | 55 | 1 |
31 Aug 18 | 34 | 27 | 44 | 1 |
31 May 18 | 28 | 23 | 34 | 0 |
28 Feb 18 | 24 | 25 | 22 | 0 |
30 Nov 17 | 20 | 18 | 16 | 0 |
31 Aug 17 | 18 | 15 | 14 | 0 |
31 May 17 | 15 | 3 | 10 | 0 |
28 Feb 17 | 13 | 6 | 9 | 0 |
30 Nov 16 | 11 | 2 | 7 | 0 |
31 Aug 16 | 9 | 1 | 6 | 0 |
31 May 16 | 6 | 0 | 5 | 0 |
29 Feb 16 | 5 | -1 | 4 | 0 |
30 Nov 15 | 3 | -3 | 3 | 0 |
31 Aug 15 | 1 | -4 | 3 | 0 |
31 May 15 | 0 | -5 | 3 | 0 |
28 Feb 15 | 0 | -5 | 3 | 0 |
30 Nov 14 | 0 | -3 | 3 | 0 |
31 Aug 14 | 0 | -3 | 2 | 0 |
Quality Earnings: TLRY is currently unprofitable.
Growing Profit Margin: TLRY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TLRY is unprofitable, and losses have increased over the past 5 years at a rate of 36.9% per year.
Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: TLRY has a negative Return on Equity (-5.78%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 02:04 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/08/31 |
Annual Earnings | 2024/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tilray Brands, Inc. is covered by 31 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Aaron Grey | Alliance Global Partners |
Frederico Yokota Choucair Gomes | ATB Capital Markets |
Gaurav Jain | Barclays |